Legal Representation
Attorney
CHRISTINA M. LICURSI
USPTO Deadlines
Next Deadline
169 days remaining
NOA E-Mailed - SOU Required
Due Date
June 09, 2026
Extension Available
Until December 09, 2026
Application History
23 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 9, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 30, 2025 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Oct 30, 2025 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Oct 30, 2025 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Jul 20, 2025 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Jul 18, 2025 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Apr 24, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 24, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 24, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 14, 2025 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Jan 21, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 21, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 15, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 24, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 25, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 25, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 25, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 2, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 2, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 2, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 2, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 28, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 4, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in gene therapy; biological and pharmaceutical preparations, both comprised of therapeutic nucleic acids, namely RNA, for the treatment and prevention of genetic diseases and disorders, genomic diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders; therapeutic preparations to modulate metabolism; pharmaceutical preparations and agents to modulate metabolism; pharmaceutical agents that modulate metabolism for scientific and research use; therapeutic pharmaceuticals for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; pharmaceutical preparations for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; therapeutic pharmaceuticals for modulating metabolism; none of the foregoing for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), osteoarthritis, or limb spasticity
Class 042
Testing, inspection, research, and development of pharmaceutical preparations for gene therapy; research and development in the field of computational biology, biotechnology and pharmaceuticals; none of the foregoing related to the treatment of pyruvate dehydrogenase complex deficiency (PDCD), osteoarthritis, or limb spasticity
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOMEDICINES"